Tevogen.AI Expands Collaboration with Microsoft and Databricks to Develop Beta Version of PredicTcell Model
ByAinvest
Wednesday, Aug 13, 2025 3:53 pm ET1min read
MSFT--
The enhanced model will combine a new oncology dataset with existing virology data to enhance prediction accuracy for cancer and infectious disease therapies. Led by CIO Mittul Mehta, Tevogen.AI is addressing the challenges in oncology drug discovery, particularly the complexity of the disease and the limited availability of high-quality datasets [1].
The collaboration leverages the Databricks Data Intelligence Platform and Microsoft's innovative engineering teams to curate a dataset focused on oncology. This dataset, when aggregated with the initial virology dataset, aims to improve upon the accuracy of the alpha version of the PredicTcell model [1].
Tevogen.AI's recent international patent (WO 2025/129197) outlines novel machine learning systems for predicting immunologically active peptides, a critical step in developing targeted therapies for cancers and infectious diseases. The company's forward-looking statements highlight potential benefits and risks associated with this initiative [1].
In addition to the beta version of the PredicTcell model, Tevogen.AI plans to develop enhanced analytics and visualization tools for its internal R&D teams. The company is also exploring external market opportunities as a potential revenue source [1].
The global AI in healthcare market is expected to hit nearly $700 billion by 2034, growing at an explosive 38.5% CAGR. This growth is driven by advancements in AI-powered diagnostics and drug discovery, with companies like Tevogen.AI at the forefront of innovation [2].
References:
[1] https://www.stocktitan.net/news/TVGNW/repeat-tevogen-ai-expands-collaboration-with-databricks-and-wjyia4kf1q4u.html
[2] https://www.prnewswire.com/news-releases/healthcare-ai-market-explodes-38-5-annually-as-diagnostics-gain-fda-traction-302527904.html
Tevogen.AI, in collaboration with Microsoft and Databricks, is developing the beta version of its PredicTcell model with a focus on oncology. The model aims to enhance accuracy and diversity, potentially accelerating cancer immunotherapy development. Tevogen.AI will also develop enhanced analytics and visualization tools for its internal R&D teams. Additionally, the company plans to explore external market opportunities as a potential revenue source.
Tevogen.AI (NASDAQ: TVGNW) has announced an expanded collaboration with Microsoft (NASDAQ: MSFT) and Databricks to develop the beta version of its PredicTcell™ model, with a focus on oncology applications. This initiative aims to improve the accuracy and diversity of the model, potentially accelerating the development of cancer immunotherapy [1].The enhanced model will combine a new oncology dataset with existing virology data to enhance prediction accuracy for cancer and infectious disease therapies. Led by CIO Mittul Mehta, Tevogen.AI is addressing the challenges in oncology drug discovery, particularly the complexity of the disease and the limited availability of high-quality datasets [1].
The collaboration leverages the Databricks Data Intelligence Platform and Microsoft's innovative engineering teams to curate a dataset focused on oncology. This dataset, when aggregated with the initial virology dataset, aims to improve upon the accuracy of the alpha version of the PredicTcell model [1].
Tevogen.AI's recent international patent (WO 2025/129197) outlines novel machine learning systems for predicting immunologically active peptides, a critical step in developing targeted therapies for cancers and infectious diseases. The company's forward-looking statements highlight potential benefits and risks associated with this initiative [1].
In addition to the beta version of the PredicTcell model, Tevogen.AI plans to develop enhanced analytics and visualization tools for its internal R&D teams. The company is also exploring external market opportunities as a potential revenue source [1].
The global AI in healthcare market is expected to hit nearly $700 billion by 2034, growing at an explosive 38.5% CAGR. This growth is driven by advancements in AI-powered diagnostics and drug discovery, with companies like Tevogen.AI at the forefront of innovation [2].
References:
[1] https://www.stocktitan.net/news/TVGNW/repeat-tevogen-ai-expands-collaboration-with-databricks-and-wjyia4kf1q4u.html
[2] https://www.prnewswire.com/news-releases/healthcare-ai-market-explodes-38-5-annually-as-diagnostics-gain-fda-traction-302527904.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet